SUSMED, Inc.

SUSMED, Inc., a small-cap pharmaceutical company, saw its stock price drop significantly today, despite a strong annual performance. The company faces challenges with low profitability and negative EBITDA, raising concerns about its financial health amid recent market fluctuations and contrasting performance with the Japan Nikkei 225 index.

SUSMED, Inc. has seen a notable rise in its stock price, with significant gains over various time frames, including a 90.55% increase over the past year. However, the company faces challenges such as low return on equity and negative EBITDA, indicating potential financial risks ahead.

SUSMED, Inc., a small-cap pharmaceutical company, saw its stock rise significantly on March 5, 2026, despite a broader market decline. Over the past month, it has outperformed the Nikkei 225, but faces challenges with low profitability metrics and a notable decline over the past three years.

SUSMED, Inc. has faced notable volatility, with a significant decline in stock price today. Despite a yearly return of 60.14%, the company struggles with financial challenges, including a low return on equity and negative EBITDA. Its market capitalization stands at JPY 16,109 million amid a challenging trading environment.

SUSMED, Inc. has transitioned from a 'Not Rated' status to a 'Sell' designation by MarketsMOJO, reflecting a change in its technical score. The company's mixed technical indicators and long-term fundamentals reveal challenges, including low profitability and negative EBITDA, despite some positive year-over-year returns.